Correlation Engine 2.0
Clear Search sequence regions


  • cat (1)
  • coronavirus (2)
  • diagnosis (1)
  • EGFR (1)
  • gene (1)
  • humans (1)
  • ICAM1 (1)
  • IL10 (1)
  • MAPK1 (1)
  • MAPK14 (1)
  • oxygen (1)
  • patients (1)
  • pneumonia (1)
  • pneumonia viral (1)
  • PRKCB (1)
  • signal (1)
  • vitamins (13)
  • Sizes of these terms reflect their relevance to your search.

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an epidemic disease characterized by rapid infection and a high death toll. The clinical diagnosis of patients with COVID-19 has risen sharply, especially in Western countries. Globally, an effective treatment for COVID-19 is still limited. Vitamin A (VA) exhibits pharmacological activity in the management of pneumonia. Thus, we reason that VA may potentially serve as an anti-SARS-CoV-2 regimen. In this study, bioinformatics analysis and computation assays using a network pharmacology method were conducted to explore and uncover the therapeutic targets and mechanisms of VA for treating COVID-19. We identified candidate targets, pharmacological functions, and therapeutic pathways of VA against SARS-CoV-2. Bioinformatics findings indicate that the mechanisms of action of VA against SARS-CoV-2 include enrichment of immunoreaction, inhibition of inflammatory reaction, and biological processes related to reactive oxygen species. Furthermore, seven core targets of VA against COVID-19, including MAPK1, IL10, EGFR, ICAM1, MAPK14, CAT, and PRKCB were identified. With this bioinformatics-based report, we reveal, for the first time, the anti-SARS-CoV-2 functions and mechanisms of VA and suggest that VA may act as a potent treatment option for COVID-19, a deadly global epidemic.

    Citation

    Rong Li, Ka Wu, Yu Li, Xiao Liang, William Ka Fai Tse, Lu Yang, Keng Po Lai. Revealing the targets and mechanisms of vitamin A in the treatment of COVID-19. Aging. 2020 Aug 15;12(15):15784-15796

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 32805728

    View Full Text